Trial Profile
Phase I/II trial of Abraxane (ABI-007) [paclitaxel] and Alimta (pemetrexed) in advanced solid tumors with emphasis on non-small cell lung cancer (NSCLC) and breast cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pemetrexed (Primary)
- Indications Breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 16 May 2017 Status changed from completed to discontinued.
- 16 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 29 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.